Endocrinology and Metabolism

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

Sang Youl Rhee

Endocrinol Metab. 2020;35(1):192-193. Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.192

Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

Han Na Jang, Hye Seung Jung

Endocrinology and Metabolism. 2020;35(1):194

Link1 Link2 Link3

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)

Sang Youl Rhee

Endocrinology and Metabolism. 2020;35(1):192

Link1 Link2 Link3

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes

Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung

Endocrinology and Metabolism. 2019;34(4):382

Link1 Link2 Link3

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial

Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi

Diabetes & Metabolism Journal. 2020;44(4):532

Link1 Link2 Link3

Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

Y. Onishi, Y. Ono, R. Rabøl, L. Endahl, S. Nakamura

Diabetes, Obesity and Metabolism. 2013;15(9):826-832

Link1 Link2 Link3 Link4

Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study

S. Kumar, H. C. Jang, N. G. Demirağ, T. V. Skjøth, L. Endahl, B. Bode

Diabetic Medicine. 2016;34(2):180-188

Link1 Link2 Link3

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes

E. Franek, M. Haluzík, S. Canecki Varžić, M. Sargin, S. Macura, J. Zacho, J. S. Christiansen

Diabetic Medicine. 2015;33(4):497-505

Link1 Link2 Link3

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)

I. B. Hirsch, E. Franek, H. Mersebach, L. Bardtrum, K. Hermansen

Diabetic Medicine. 2016;34(2):167-173

Link1 Link2 Link3

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial

John B. Buse, Anders L. Carlson, Mitsuhisa Komatsu, Ofri Mosenzon, Ludger Rose, Bo Liang, Kristine Buchholtz, Hiroshi Horio, Takashi Kadowaki

Diabetes, Obesity and Metabolism. 2018;20(12):2885-2893

Link1 Link2

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues

Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova

Diabetes mellitus. 2014;17(4):108-119

Link1 Link2